

研究成果の刊行に関する一覧表（平成21年度）

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
正木尚彦	IFN治療に対する医療費助成 —現状とその利用の仕方—	Medical Practice	27(1)	99-102	2010
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda N, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, <u>Izumi N.</u>	A Predictive Model of Response to Peginterferon Ribavirin in Chronic Hepatitis C using Classification and Regression Tree Analysis.	Hepatol Res.	40(3)	251-260	2010
Itakura J, Kurosaki M, Itakura Y, Maekawa S, Asahina Y, <u>Izumi N,</u> Enomoto N.	Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model.	Biosystems.	99	70-78	2010
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga, M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, <u>Masaki N,</u> Sugauchi F, <u>Izumi N,</u> Tokunaga K, Mizokami M.	Genome-wide association of IL28B with response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C.	Nat Genet.	41	1105-9	2009
Iwasaki Y, Shiratori Y, Hige S, Nishiguchi S, Takagi H, Onji M, Yoshida H, <u>Izumi N,</u> Kohgo Y, Yamamoto K, Sato N, Shibuya A, Saito H, Sata M, Suzuki K, Kaneko S, Moriyama M, Omata M.	A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a in patients infected with chronic hepatitis C virus genotype 2 or low viral load genotype 1: a multi-center national study in Japan.	Hepatol Int.	3	468-479	2009
Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, <u>Izumi N,</u> Akuta N, Kumada H.	Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study.	J Gastroenterol.	44	952-63	2009

泉 並木	ウイルス肝炎検診と病診連携のすすめかた	Medical Practice	27	95-98	2010
泉 並木	肝炎が発症したらどう対応すればよいでしょうか？	腎と透析	66	647-650	2009
泉 並木	肝癌再発予防にIFN, PEG-IFN/Ribaはどれだけ有効か？	肝胆膵	58	655-662	2009
泉 並木	高齢者C型慢性肝炎における発がん抑止戦略	腫瘍内科	3	556-563	2009
泉 並木	B型・C型肝炎の日常診療	東京内科医会誌	25(1)	6-9	2009
Salim EI, <u>Sobue T</u> , et al.	Cancer epidemiology and control in the arab world-past, present and future.	Asian Pac J Cancer Prev.	10(1)	3-16	2009
Saika K, <u>Sobue T</u> .	Epidemiology of Breast Cancer in Japan and the US.	Jpn Med Assoc J.	52(1)	39-44	2009
Moore MA, <u>Sobue T</u> .	Cancer research and control activities in Japan: contributions to international efforts.	Asian Pac J Cancer Prev.	10(2)	183-200	2009
Matsuda T, <u>Sobue T</u> , et al.	Cancer Incidence and Incidence Rates in Japan in 2003: Based on Data from 13 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project.	Jpn J Clin Oncol.	39(12)	850-8	2009
Katanoda K, <u>Sobue T</u> , et al.	Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.	J Epidemiol.	19(5)	266-270	2009
祖父江友孝	がん対策としてのがん検診と有効性評価.	がん検診・診断学会誌	16(3)	30-35	2009
Mori N, Imamura M, Kawakami Y, Kawaoka T, Saneto H, Takaki S, Aikata H, <u>Takahashi S</u> , Chayama K; Hiroshima Liver Study Group.	Randomized Trial of High-Dose Interferon- α -2b Combined With Ribavirin in Patients With Chronic Hepatitis C:Correlation Between Amino Acid Substitutions in the Core/NS5A Region and Virological Response to Interferon Therapy.	J Med Virol.	81	640-9	2009

Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, Kawakami H, Jeong SC, Imamura M, Aikata H, Takahashi S, Chayama K.	Dose comparison study of pegylated interferon- α -2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.	J Gastroenterol Hepatol.	24	366-71	2009
高橋祥一, 茶山一彰.	高齢者・女性のC型肝炎患者に対する治療.	消化器の臨床	12	55-59	2009
高橋祥一, 茶山一彰.	C型肝炎に対するペグインターフェロン α -2bとリバビリン併用療法の治療成績.	消化器科	49	119-23	2009
高橋祥一, 茶山一彰.	C型肝炎治療の最前線.	細胞	31	235-38	2009
酒井明人, 金子周一.	HCVの最新療法—DFPP療法を中心に—.	医学と薬学	62(3)	404-409	2009
酒井明人, 金子周一.	石川県の肝癌撲滅戦略—モデルケースとして—.	内科	104(4)	661-665	2009
酒井明人, 金子周一.	C型肝炎治療と遺伝子情報.	治療学	43(3)	295-298	2009

研究成果の刊行に関する一覧表（平成22年度）

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
黒崎雅之、 <u>泉並木</u>	B型肝炎に対する抗ウイルス治療	林紀夫、日比紀文、上西紀夫	Annual Review 消化器	中外医学社	東京	2011	137-45
田中智大、 <u>泉並木</u>	肝臓癌	佐藤千史、井上智子	人体の構造と機能からみた病態生理	金原出版	東京	2010	93-100
工藤正俊、 <u>泉並木</u>	序文	工藤正俊、 <u>泉並木</u>	ウイルス肝炎の治療戦略	診断と治療社	東京	2010	vi-vii

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
正木尚彦、西村 崇、忌部航、山田晃弘、柳瀬幹雄、矢野公士、伊藤清顕、今村雅俊、伊東和樹、宜保行雄、垣内雅彦、川上由育、川上広育、畠山重秋、小松真史、金 守良、八橋 弘、 <u>泉並木</u> 、野村秀幸、西原利治、中尾春壽、米田政志、平松直樹、林 紀夫、溝上雅史	ペグインターフェロン治療における診療アクセスの改善策に関する多施設共同研究～前向き研究と後ろ向き研究からの考察～	肝臓	51(7)	348-360	2010
正木尚彦	肝炎対策基本法をめぐる話題。特集 肝炎対策基本法	医学情報誌 シュネラー	75	11-17	2010
正木尚彦	肝疾患診療連携拠点病院のミッション	肝胆膵	61(増刊号)	20-27	2010
正木尚彦	肝炎情報センターの役割	肝胆膵	61(5)	721-729	2010
<u>泉並木</u>	ペグインターフェロン・リビリン併用療法とその効果予測	Current Therapy	28	25-29	2010
<u>泉並木</u>	ウイルス性慢性肝炎の最近の治療	日本医事新報	4500	59-64	2010
<u>泉並木</u>	データマイニングによる病態解析	最新医学	65	1901-6	2010
<u>泉並木</u>	肝疾患の地域連携計画	肝胆膵	61	847-52	2010

Izumi N, Asahina Y, Kurosaki M.	Predictions of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.	Hepat Res Treat press	In press		2011
Izumi N.	Recent advances of radiofrequency ablation for early hepatocellular carcinoma.	J Gastroenterol Hepatol	26S	115-22	2011
Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, <u>Izumi N.</u>	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	52	518-27	2010
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, <u>Izumi N, Mizokami M.</u>	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54(3)	439-448	2011
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, <u>Izumi N.</u>	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: Dta maining analysis.	J Med Virol	83(3)	445-452	2011

Izumi N.	Diagnosis and treatment algorithm of the Japanese society of Hepatology: a consensus-based practice guideline.	Oncology	78	78-86	2010
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N.	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.	Hepatol Res	40	870-7	2010
Yokosuka O, Kurosaki M, Imazeki F, Arase Y, Tanaka Y, Chayama K, Tanaka E, Kumada H, Izumi N, Mizokami M, Kudo M.	Management of hepatitis B: consensus of the Japan Society of Hepatology 2009.	Hepatol Res	41	1-21	2011
Chayama K, Hayes CN, Yoshida K, Moriwaki H, Okanoue T, Sakisaka S, Takehara T, Oketani M, Toyota J, Izumi N, Hiasa Y, Matsumoto A, Nomura H, Seike M, Ueno Y, Yotsuyanagi H, Kumada H.	Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C.	Hepatol Res	40	1155-67	2010
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Yatsuhashi H, Izumi N.	Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.	J Gastroenterol	In press		2010

<p>Karino Y, Toyota J, Kumada H, Katano Y, <u>Izumi N</u>, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M, Ishikawa H, Masaki N, Seriu T, Omata M.</p>	<p>Efficacy and resistance of entecavir following 3 years of treatment of Jananese patients with lamivudine-refractory chronic hepatitis B.</p>	<p>Hepatol Int</p>	<p>4</p>	<p>414-22</p>	<p>2010</p>
<p><u>Namiki I</u>, Nishiguchi S, Hino K, Suzuki F, Kumada H, Itoh Y, Asahina Y, Tamori A, Hiramatsu N, Hayashi N, Kudo M.</p>	<p>Management of hepatitis C; report of the consensus meeting at the 45th annual meeting of the Japan Society of Hepatology (2009).</p>	<p>Hepatol Res</p>	<p>40</p>	<p>347-68</p>	<p>2010</p>
<p>Kumada H, Okanoue T, Onji M, Moriwaki H, <u>Izumi N</u>, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y; The Study Group for the Standardization of Treatment of Viral Hepatitis including Cirrhosis, Ministry of Health, Labor and Welfare of Japan.</p>	<p>Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan.</p>	<p>Hepatol Res</p>	<p>40</p>	<p>1-7</p>	<p>2010</p>
<p>Kumada H, Okanoue T, Onji M, Moriwaki H, <u>Izumi N</u>, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y ; The Study Group for the Standardization of Treatment of Viral Hepatitis including Cirrhosis, Ministry of Health, Labor and Welfare of Japan.</p>	<p>Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan.</p>	<p>Hepatol Res</p>	<p>40(1)</p>	<p>8-13</p>	<p>2010</p>

Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT study group.	Prolonged treatment with pegylated interferon alpha2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.	Hepatol Res	40	135-44	2010
祖父江友孝	がん登録の進歩	腫瘍内科	7 (1)	56-61	2011
祖父江友孝	臨床家にとっての地域がん登録の意義、今後の展望	外科治療	102	346-352	2010
東尚弘 祖父江友孝 西本寛	臓器がん登録の現状—臓器がん登録の実態についての調査報告—	外科治療	104	169-176	2011
Sobue T, Inoue M, Tanaka H.	Cancer Registry and Epidemiological Study Working Group report.	Jpn J Clin Oncol	Suppl 1	176-81	2010
Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T Japan Cancer Surveillance Research Group.	Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project	Jpn J Clin Oncol	41(1)	139-47	2011
Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T Research Group of Population-Based Cancer Registries of Japan.	Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: achronological and international comparative study	Jpn J Clin Oncol	41(1)	40-51	2011
Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T Japan Cancer Surveillance Research Group.	Cancer incidence and incidence rates in Japan in 2004: based on data from 14 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project.	Jpn J Clin Oncol	40 (12)	1192-200	2010
Matsuda T, Marugame T, Ajiki W, Sobue T.	Do the Japanese feel more suspicious about cancer registration than the British?	Cancer Epidemiol	34(2)	122-30	2010
高橋祥一, 茶山一彰	広島県におけるC型肝炎の診療体制作り.	肝胆膵	61(5)	773-9	2010

Abe H, Ochi H, Maekawa T, Hayes CN, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, <u>Takahashi S</u> , Ohishi W, Arihiro K, Kubo M, Nakamura Y, Chayama K.	Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.	J Hepatol	53(3)	439-43	2010
Kawaoka T, Hiraga N, <u>Takahashi S</u> , Takaki S, Mitsui F, Tsuge M, Nagaoki Y, Kimura Y, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Aikata H, Tashiro H, Ohdan H, Chayama K.	Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus	Scand J Gastroenterol	45(12)	488-96	2010
Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, Tsuge M, Mitsui F, Hiraga N, Imamura M, <u>Takahashi S</u> , Kubo M, Tsunoda T, Nakamura Y, Kumada H, Chayama K.	Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.	J Hepatol	54(3)	408-14	2011
Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, <u>Takahashi S</u> , Kubo M, Nakamura Y, Chayama K.	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.	J Hepatol	Feb 4	Epub ahead of print	2011
Kitamura S, Tsuge M, Hatakeyama T, Abe H, Imamura M, Mori N, Saneto H, Kawaoka T, Mitsui F, Hiraga N, Takaki S, Kawakami Y, Aikata H, <u>Takahashi S</u> , Ohishi W, Ochi H, Hayes CN, Chayama K.	Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy.	Antivir Ther	15(8)	1087-97	2010
酒井明人, 金子周一	肝疾患の地域医療連携 各地域の取り組み 石川県の取り組み	肝胆膵	61	753-761	2010
酒井明人, 金子周一	インターフェロン+DFPP 併用療法	消化器の臨床	13	310-314	2010
酒井明人, 金子周一	C型肝炎における VRAD の有用性	医学のあゆみ	234	1197-1201	2010

酒井明人, 金子周一	よく見かける感染症 診断・治療の最新事情 ウイルス肝炎の現状撲滅への取り組み	内科	106	825-829	2010
Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S; Hokuriku Liver Study Group	Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C	Gastroenterology	139	499-509	2010
新保卓郎	「医学知識」の生存期間	日本医師会雑誌	139(6)	1256	2010
新保卓郎	IV. 診療ガイドライン 3. 有効性	日内会誌	99(12)	3042-3046	2010
八橋 弘、松本武浩	特集 肝疾患の地域連携医療—肝疾患診療連携拠点病院、公費助成制度、治療計画の運用—長崎県での医療連携—IFN 手帳とあじさいネット：—)	肝胆膵	61(5)	819-827	2010

研究成果の刊行に関する一覧表（平成 23 年度）

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
泉 並木	ウイルスおよび宿主因子に基づいたC型肝炎の治療	森正樹、下瀬川徹、金子周一、松本俊治、寺田弘司	消化器疾患の最新医療	先端医療技術研究所	東京	2011	104-107
泉 並木	健康診断で肝臓の数値が気になるとき読む本	泉 並木	健康診断で肝臓の数値が気になるとき読む本	幻冬舎	東京	2011	全部
泉 並木	肝臓の治療	林紀夫、日比紀文、西紀夫、下瀬川徹	Annual Review消化器2012	中外医学社	東京	2012	174-184
泉 並木	ウイルス肝炎の治療戦略 序文	工藤正俊、泉 並木	ウイルス肝炎の治療戦略	診断と治療社	東京	2010	vii
三浦美香、前川伸哉、門倉信、末木良太、小馬瀬一樹、進藤浩子、進藤邦明、雨宮史武、中山康弘、植竹智義、井上泰輔、坂本穰、榎本信幸	肝発癌に関連するC型肝炎ウイルス遺伝子領域とIL28B SNP の解析	小俣政男	第 18 回浜名湖シンポジウム記録集 消化器疾患と幹細胞；その基礎と臨床	アークメディア	日本	2011年	171-177

雑誌

発表者氏名	論文タイトル名	発表誌名	巻・号	ページ	出版年
正木尚彦	ウイルス肝炎検診と病診連携の重要性と進めかた	Medical Practice	28 巻 8 号	1453-1457	2011

Ito K, Higami K, <u>Masaki N</u> , Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Higase S, Adachi H, Hino K, Yatsushashi H, Orito E, Kani S, Tanaka Y, Mizokami M.	The rs8099917 polymorphism, determined by a suitable genotyping method, is a better predictor for response to pegylated interferon-alpha/ ribavirin therapy in Japanese patients than other SNPs associated with IL28B.	J Clin Microbiol	49 卷 5 号	1853-1860	2011
Tamada Y, Yatsushashi H, <u>Masaki N</u> , Nakamura M, Mita E, Komatsu T, Watanabe Y, Shimada M, Hijioka T, Satoh T, Mano Y, Komeda T, Takahashi M, Kohno H, Ota H, Hayashi S, Miyakawa Y, Abiru S, Ishibashi H.	Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B.	Gut			2011 Nov 7. [Epub ahead of print]
Asahina Y, <u>Izumi N</u> et al.	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.	Hepatol	55	20-9	2012
Kurosaki M, <u>Izumi N</u> , et al.	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	In press		2012
Kurosaki M, <u>Izumi N</u> , et al.	Relationship between polymorphisms of the inosine triphosphate gene and anemia or outcome after treatment with pegylated interferon and ribavirin.	Antivir Ther	16	685-94	2011
Itakura J, <u>Izumi N</u> et al.	Changes days can predict the undetectable time in hepatitis C viral load during first 14 point of serum viral load by pegylated interferon and ribavirin therapy.	Hepatol Res	41	217-24	2011

Watanabe S, <u>Izumi N</u> et al.	Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res	41	955-64	2011
Shindo H, Enomoto N, <u>Izumi N</u> et al.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients	Hepatol Int	In press		2011
Kurosaki M, <u>Izumi N</u> , et al.	Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis.	J Med Virol	83	445-52	2011
<u>Izumi N</u> , Asahina Y et al.	Predictions of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors.	Hepat Res Treat	2010	703602	2010
Kurosaki M, <u>Izumi N</u> , et al.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol	54	439-48	2011
Kurosaki M, <u>Izumi N</u> , et al.	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.	Hepatol Res	40	870-7	2010
Asahina Y, <u>Izumi N</u> , et al.	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	52	518-27	2010
Itakura J, <u>Izumi N</u> et al.	Reproducibility and usability of chronic virus infection model using agent-based simulation; comparing with a mathematical model.	Biosystems	99	70-8	2010

Hiramatsu N, <u>Izumi N</u> , et al.	Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.	J Gastroenterol	46	1111-9	2011
Tsuchiya K, <u>Izumi N</u> et al.	Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.	Oncology	80	278-88	2011
Kuzuya T, <u>Izumi N</u> et al.	Early decrease in α -fetoprotein but not des- γ -carboxy prothrombin predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.	Oncology	81	251-8	2011
Kawaguchi T, <u>Izumi N</u> et al.	Branched-chain amino acids as pharmacological nutrients in chronic liver disease.	Hepatology	54	1063-70	2011
<u>Izumi N</u>	Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.	Hepatol Res	In press		2012
Tamada Y, <u>Yatsuhashi H</u> , Masaki N, Nakamuta M, Mita E, Komatsu T, Watanabe Y, Muro T, Shimada M, Hijioka T, Satoh T, Mano Y, Komeda T, Takahashi M, Kohno H, Ota H, Hayashi S, Miyakawa Y, Abiru S, Ishibashi H.	Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B	Gut.			2011 (in press)
Miyaaki H, Ichikawa T, <u>Yatsuhashi H</u> , Taura N, Miura S, Usui T, Mori S, Kamihira S, Tanaka Y, Mizokami M, Nakao K.	Suppressor of cytokine signal 3 and IL28 genetic variation predict the viral response to peginterferon and ribavirin	Hepatol Res	41(12)	1216-1222	2011

Kawaguchi T, Kakuma T, Yatsuhashi H, Watanabe H, Saitsu H, Nakao K, Taketomi A, Ohta S, Tabaru A, Takenaka K, Mizuta T, Nagata K, Komorizono Y, Fukuizumi K, Seike M, Matsumoto S, Maeshiro T, Tsubouchi H, Muro T, Inoue O, Akahoshi M, Sata M.	Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma	Hepatology Res	41(6)	564-571	2011
Ozawa E, Abiru S, Nagaoka S, Yano K, Komori A, Migita K, Yatsuhashi H, Taura N, Ichikawa T, Ishibashi H, Nakao K.	Ferritin/alanine aminotransferase ratio as a possible marker for predicting the prognosis of acute liver injury	J Gastroenterol Hepatol	26(8)	1326-1332	2011
Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, Murata K, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M.	The rs8099917 Polymorphism, Determined by a Suitable Genotyping Method, is a Better Predictor for Response to Pegylated Interferon- α /Ribavirin Therapy in Japanese Patients than Other SNPs Associated with IL28B	J Clin Microbiol	49(5)	1853-1860	2011
Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T; The Japan Cancer Surveillance Research Group.	Cancer Incidence and Incidence Rates in Japan in 2006: Based on Data from 15 Population-based Cancer Registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project.	Jpn J Clin Oncol	42(2)	139-147	2012

Katanoda K, Ajiki W, Matsuda T, Nishino Y, Shibata A, Fujita M, Tsukuma H, Ioka A, Soda M, <u>Sobue T</u> .	Trend analysis of cancer incidence in Japan using data from selected population-based cancer registries.	Cancer Sci	103(2)	360-368	2012
東尚弘、祖父江友孝、西本寛.	臓器がん登録の現状。—臓器がん登録の実態についての調査報告—。	外科治療	104(2)	169-176	2011
<u>Shimbo. T</u> , Nagata-Kobayashi. S, Masaki. N, Study Group Developing Nationwide Database of Hepatitis Japan	Cost-Effectiveness of Peginterferon and Ribavirin for Elderly Patients with Chronic Hepatitis C: Results Based on the Nationwide Hepatitis Registration in Japan.	Value in Health	14(7)	A395	2011
Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, Mitsui F, Hiraga N, Imamura M, <u>Takahashi S</u> , Kubo M, Nakamura Y, Chayama K.	IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.	J Hepatol	54(6)	1094-101	2011
Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsui F, Hiraga N, Imamura M, <u>Takahashi S</u> , Nelson Hayes C, Ohishi W, Kubo M, Tsunoda T, Kamatani N, Nakamura Y, Chayama K.	Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.	J Med Virol	83(6)	981-8	2011
Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, <u>Takahashi S</u> , Ochi H, Nakamura Y, Kamatani N, Chayama K.	Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.	J Med Virol	83(6)	1048-57	2011

Hiraga N, Abe H, Imamura M, Tsuge M, <u>Takahashi S</u> , Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K.	Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.	Hepatology	54(3)	764-71	2011
酒井明人、荒井邦明、金子周一	肝臓癌の予防とサーベイランス	G.I.Research	19	334-341	2011
Honda M, Takehana K, <u>Sakai A</u> , Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S; Hokuriku Liver Study Group	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C	Gastroenterology	141	128-140	2011
Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, <u>Inoue T</u> , Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N	Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy.	Hepatology Int	5(3)	789-99	2011

<p>Kadokura M, Maekawa S, Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, <u>Inoue T</u>, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N</p>	<p>Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.</p>	<p>PLoS One</p>	<p>6(9):e24514. Epub</p>		<p>2011</p>
<p>Shindo H, Maekawa S, Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, <u>Inoue T</u>, Sakamoto M, Okada SI, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N</p>	<p>Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.</p>	<p>Hepato Int</p>	<p>Aug 18.Epub ahead of print</p>		<p>2011</p>
<p>Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, <u>Inoue T</u>, Sakamoto M, Okada S, Enomoto N</p>	<p>Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.</p>	<p>Hepato Int</p>	<p>2011 Aug 17.Epub ahead of print</p>		<p>2011</p>

